Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/13/2025 | $86.00 | Equal Weight | Barclays |
| 10/7/2025 | $83.00 | Buy → Neutral | Citigroup |
| 5/5/2025 | $73.00 | Sell → Neutral | UBS |
| 3/11/2025 | $85.00 → $100.00 | Neutral → Buy | Goldman |
| 1/8/2025 | $95.00 → $103.00 | Hold → Buy | Jefferies |
| 9/26/2024 | $84.00 → $74.00 | Neutral → Sell | UBS |
| 9/18/2024 | $100.00 | Neutral → Buy | BTIG Research |
| 9/9/2024 | $90.00 | Neutral | JP Morgan |
Barclays initiated coverage of GE HealthCare with a rating of Equal Weight and set a new price target of $86.00
Citigroup downgraded GE HealthCare from Buy to Neutral and set a new price target of $83.00
UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00
144 - GE HealthCare Technologies Inc. (0001932393) (Subject)
144 - GE HealthCare Technologies Inc. (0001932393) (Subject)
SCHEDULE 13G - GE HealthCare Technologies Inc. (0001932393) (Subject)
Informed by clinicians and built on clinical insights, the solution provides care teams with real-time1 insights designed to streamline perinatal workflows and support timely clinical decision-making. Developed in collaboration with HCA Healthcare, one of the nation's leading healthcare providers, this solution includes clinical input that helps ensure practical functionality that will help clinicians stay focused on patient care. The solution is part of GE HealthCare's CareIntellect family of clinical and operational applications; built to allow hospitals to integrate once and add more applications quickly and cost-effectively. GE HealthCare (NASDAQ:GEHC) today announced the laun
The retrospective analysis of nearly 15,000 general anesthesia cases of adults (18 years and older) at the University of Michigan demonstrated End-tidal Control's association with reduced anesthetic agent usage and greenhouse gas emissions. End-tidal Control is the first and only FDA-approved software that automatically adjusts to maintain end-tidal oxygen and end-tidal anesthetic agent concentrations set by the clinician, with more accuracy in reaching the clinician's targets versus manual control. The GE HealthCare booth (#1314) at ANESTHESIOLOGY 2025 showcases the company's advancing perioperative care portfolio that supports clinical workflows and individualized patient care.
Carestation 850 is designed to help health systems navigate the evolving landscape of anesthesia care now and in the future with an ergonomic design, continuously optimized algorithms, adaptable technologies and sustainable practices. With the goal of enhancing clinical precision, Carestation 850 features tools and customizable applications that are designed to help adapt to the needs of each patient, from neonates to the elderly. GE HealthCare will showcase Carestation 850 at booth #1314 during ANESTHESIOLOGY 2025 taking place from October 10-14, in San Antonio, Texas. GE HealthCare (NASDAQ:GEHC) today announced the unveiling of Carestation™ 850, its next-generation, FDA 510(k) p
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)
GE HealthCare (NASDAQ:GEHC) will announce its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical te
The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025 payable on November 14, 2025 to all shareholders of record as of October 24, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for
Revenue growth was 3% year-over-year; Organic revenue growth* was 2% Net income margin was 9.7% versus 8.9% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 14.6% versus 15.3% Diluted earnings per share (EPS) were $1.06 versus $0.93 for the prior year; Adjusted EPS* was $1.06 versus $1.00 Cash flow from operating activities was $94 million versus $(119) million for the prior year; Free cash flow* was $7 million versus $(182) million Raises full-year 2025 guidance GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2025. GE HealthCare President and CEO Peter Arduini said, "We were pleas
BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob
GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa
Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)
SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)